Emerging as a noteworthy advance in the struggle against obesity, the drug is attracting considerable attention . This treatment combines effects of two recognized GLP-1 binding agonists, liraglutide, plus an new glucose-dependent peptide component. Initial clinical findings have indicated substantial weight loss in individuals with a high BMI ,… Read More